Afzaal Hasan, Saeed Adil, Hamdani Syed Damin Abbas, Raza Amir, Gul Alvina, Babar Mustafeez Mujtaba, Rajadas Jayakumar
Department of Pharmaceutics, Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan.
Advanced Drug Delivery and Regenerative Biomaterials, Stanford University School of Medicine, Stanford, CA, United States.
Front Pharmacol. 2022 Sep 29;13:1017549. doi: 10.3389/fphar.2022.1017549. eCollection 2022.
Alternate formulation strategies need to be devised for improving the absorption and bioavailability of drug molecules administered through the intravaginal route. Enhancing the coating of vaginal mucosa can aid the achievement of this goal. The aim of the current study is to develop a mucoadhesive formulation having adequate adhesiveness, spreading, and viscosity profiles that can ensure good tissue absorption of adapalene upon intravaginal application. A combination of mucoadhesive agents has been employed, including Carbopol-934, HPMC K-15M, and xanthan gum, in varying ratios to formulate five different gels. Furthermore, a cost-effective UV-spectroscopic analytical method was developed to quantify the amount of adapalene in tested samples, both of and origin. The analytical method was validated for different parameters, including specificity, linearity, range, accuracy, precision, and ruggedness. The modified USP-II apparatus was used for dissolution studies, while pharmacokinetic validation was performed in a murine model. Of all the tested formulations, on the basis of the rheo-mechanical attributes, ACX3 performed better than the rest, including the commercially available intravaginal reference product. ACX3 had an average adhesion time of 12 min and a spread diameter of 37 mm. It showed 35 mm as average distance travelled by the diluted sample for leakage assessment. The analytical method developed for the adapalene muco-adhesive gel was within the range for all the validation parameters. For further evaluating the performance of the formulation, dissolution studies were conducted in simulated vaginal conditions which showed 94.83% of drug release within 5 minutes, while on completion of 30 min, it was measured to be 92.90%. Moreover, approximately 67% of the administered drug was recovered after 5 min of administration as evaluated through tissue recovery procedures in mice. The study aided in development of a formulation which can enhance the muco-adhesion of the drug molecule, resulting in an improved pharmacokinetic profile. Moreover, it established an efficient assay method which can be employed for and quantification of adapalene in simulated and physiological fluids.
需要设计替代的制剂策略,以提高通过阴道途径给药的药物分子的吸收和生物利用度。增强阴道黏膜的覆盖可以有助于实现这一目标。本研究的目的是开发一种具有足够黏附性、铺展性和黏度特征的黏膜黏附制剂,该制剂在阴道给药后能够确保阿达帕林的良好组织吸收。已采用多种黏膜黏附剂的组合,包括卡波姆-934、羟丙甲纤维素K-15M和黄原胶,以不同比例配制五种不同的凝胶。此外,还开发了一种经济高效的紫外光谱分析方法,用于定量测试样品中阿达帕林的含量,无论样品来源如何。该分析方法针对不同参数进行了验证,包括特异性、线性、范围、准确度、精密度和耐用性。采用改良的USP-II装置进行溶出度研究,同时在小鼠模型中进行药代动力学验证。在所有测试制剂中,基于流变力学属性,ACX3的表现优于其他制剂,包括市售的阴道参比制剂。ACX3的平均黏附时间为12分钟,铺展直径为37毫米。在泄漏评估中,稀释样品的平均移动距离显示为35毫米。为阿达帕林黏膜黏附凝胶开发的分析方法在所有验证参数范围内。为了进一步评估该制剂的性能,在模拟阴道条件下进行了溶出度研究,结果显示5分钟内药物释放率为94.83%,30分钟结束时为92.90%。此外,通过小鼠组织回收程序评估,给药5分钟后,约67%的给药药物被回收。该研究有助于开发一种能够增强药物分子黏膜黏附性的制剂,从而改善药代动力学特征。此外,它建立了一种有效的测定方法,可用于模拟和生理流体中阿达帕林的定量分析。